Beyond nuclear ERs, GPER drives rapid, non-genomic signaling; the GPER antagonist G15 reverses E2-induced proliferation in NSCLC models, supporting GPER as a selective drug target [42]. This evidence concerns the gene GPER1 and non-small cell lung carcinoma.